Press Release

<< Back
Geron to Host Analyst and Investor Meeting and Webcast on December 19, 2017
Management to be joined by external guest speaker to review imetelstat data from IMerge to be presented at the 59th American Society of Hematology Annual Meeting and Exposition

MENLO PARK, Calif., Dec. 06, 2017 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq:GERN) today announced that the company’s analyst and investor meeting to discuss imetelstat clinical data will take place in New York, N.Y., on Tuesday, December 19, 2017. The presentation will begin at 8:30 a.m. ET.

Dr. Azra Raza, M.D., Professor of Medicine and Director of the Myelodysplastic Syndromes (MDS) Center at New York-Presbyterian/Columbia University Medical Center in New York City, will present data from Part 1 of IMerge, the ongoing Phase 2/3 clinical trial of the telomerase inhibitor imetelstat in patients with lower risk MDS being conducted by Janssen Research & Development, LLC. These data have been accepted as a poster presentation at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition.

A live audio webcast of the presentation will be available through the Investors section of Geron’s website (www.geron.com) under Events. Following the live presentation, the webcast will be archived and available for replay for a period of 30 days.

To attend the meeting in person, please send an email to Gitanjali Jain Ogawa at The Trout Group (gogawa@troutgroup.com) for further information.

About the Collaboration with Janssen

On November 13, 2014, Geron entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., to develop and commercialize imetelstat for oncology, including hematologic myeloid malignancies, and all other human therapeutics uses. All regulatory, development, manufacturing and promotional activities related to imetelstat are being managed through a joint governance structure, with Janssen responsible for these activities.

About Geron

Geron is a clinical stage biopharmaceutical company focused on the collaborative development of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. For more information about Geron, visit www.geron.com.

CONTACTS:

Anna Krassowska, Ph.D.
Investor and Media Relations
650-473-7765
investor@geron.com or media@geron.com

Gitanjali Jain Ogawa
The Trout Group
646-378-2949
gogawa@troutgroup.com

Primary Logo

Geron Corporation
 Print Page |  E-mail Page | RSS Feeds RSS Feeds | E-mail Alerts E-mail Alerts